Indivior Pharmaceuticals, Inc. INDV Business Segments — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Indivior Pharmaceuticals, Inc. 's business segments — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Indivior Pharmaceuticals, Inc. 's business segments — operating income (loss)?
- Indivior Pharmaceuticals, Inc. (INDV) reported business segments — operating income (loss) of $137M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc. 's business segments — operating income (loss) changed year-over-year?
- Indivior Pharmaceuticals, Inc. 's business segments — operating income (loss) increased by 107.6% year-over-year, from $66M to $137M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc. 's business segments — operating income (loss)?
- Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc. 's business segments — operating income (loss) has grown at a 47.9% compound annual growth rate (CAGR), from -$81M to $262M.
- What does business segments — operating income (loss) mean?
- Measures the profitability of the reportable segment by subtracting operating expenses from gross profit. It serves as a key performance indicator for the segment's operational health and management's ability to control costs relative to revenue.